Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027
Description
Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027
The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period. Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing preference for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, technical issues with sample collection and storage are factors restraining the market growth to a certain extent.
Based on technology, the immunoassays segment accounted for the largest market share of the cancer/tumor profiling market
Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share of in 2021. This large share can be attributed to the its use in the diagnosis and prognosis of cancer, they aid in making appropriate treatment decisions, and adoption of these assays as the gold standard to measure the presence and concentration of analytes in a sample.
Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period
Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. During the forecast period, the lung cancer segment is expected to register the highest CAGR. This can be attributed to the increasing need for early diagnosis and the high incidence rate of lung cancer.
Based on biomarker type, the genomic biomarker segment accounted for the largest share during the forecast period
Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers. In 2021, the genomic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the advancements in high-throughput technologies and high adoption of these biomarkers during cancer diagnosis and prognosis.
Based on applications, the research application segment holds the largest market share during the forecast period
Based on application, the cancer/tumor profiling market has been segmented into research and clinical applications. In 2021, research applications accounted for the largest share of the cancer/tumor profiling market, followed by clinical applications. The large share of the research segment can be attributed to the rapidly growing field of personalized medicine and increasing funding for cancer research.
North America is expected to account for the largest share of the cancer/tumor profiling market in 2021
In 2021, North America accounted for the largest share of the cancer/tumor profiling market, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. The large share of this market segment can be attributed to the increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics and rising adoption of advanced omics technologies for cancer research.
Break of primary participants was as mentioned below:
By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
By Designation – C-level–35%, Director-level–25%, Others–40%
By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 5%, Middle East and Africa–5%
Key players in cancer/tumor profiling the market
The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), Sysmex Corporation (Japan), HTG Molecular Diagnostics, Inc. (US), Helomics Corporation (US), Caris Life Sciences (US), NanoString Technologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).
Research Coverage:
The report analyzes the cancer/tumor profiling and aims at estimating the market size and future growth potential of this market based on various segments such as technology, cancer type, biomarker type, application, and region. The report also includes a product portfolio matrix of various cancer/tumor profiling companies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by technology, cancer type, biomarker type, application, and region
Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
Market Development: Comprehensive information on the lucrative emerging markets by technology, cancer type, biomarker type, application, and region
Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.
The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period. Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing preference for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, technical issues with sample collection and storage are factors restraining the market growth to a certain extent.
Based on technology, the immunoassays segment accounted for the largest market share of the cancer/tumor profiling market
Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share of in 2021. This large share can be attributed to the its use in the diagnosis and prognosis of cancer, they aid in making appropriate treatment decisions, and adoption of these assays as the gold standard to measure the presence and concentration of analytes in a sample.
Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period
Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. During the forecast period, the lung cancer segment is expected to register the highest CAGR. This can be attributed to the increasing need for early diagnosis and the high incidence rate of lung cancer.
Based on biomarker type, the genomic biomarker segment accounted for the largest share during the forecast period
Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers. In 2021, the genomic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the advancements in high-throughput technologies and high adoption of these biomarkers during cancer diagnosis and prognosis.
Based on applications, the research application segment holds the largest market share during the forecast period
Based on application, the cancer/tumor profiling market has been segmented into research and clinical applications. In 2021, research applications accounted for the largest share of the cancer/tumor profiling market, followed by clinical applications. The large share of the research segment can be attributed to the rapidly growing field of personalized medicine and increasing funding for cancer research.
North America is expected to account for the largest share of the cancer/tumor profiling market in 2021
In 2021, North America accounted for the largest share of the cancer/tumor profiling market, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. The large share of this market segment can be attributed to the increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics and rising adoption of advanced omics technologies for cancer research.
Break of primary participants was as mentioned below:
By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
By Designation – C-level–35%, Director-level–25%, Others–40%
By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 5%, Middle East and Africa–5%
Key players in cancer/tumor profiling the market
The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), Sysmex Corporation (Japan), HTG Molecular Diagnostics, Inc. (US), Helomics Corporation (US), Caris Life Sciences (US), NanoString Technologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US).
Research Coverage:
The report analyzes the cancer/tumor profiling and aims at estimating the market size and future growth potential of this market based on various segments such as technology, cancer type, biomarker type, application, and region. The report also includes a product portfolio matrix of various cancer/tumor profiling companies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by technology, cancer type, biomarker type, application, and region
Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
Market Development: Comprehensive information on the lucrative emerging markets by technology, cancer type, biomarker type, application, and region
Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.
Table of Contents
295 Pages
- STUDY OBJECTIVES
- MARKET DEFINITION
- CURRENCY CONSIDERED
- STAKEHOLDERS
- SUMMARY OF CHANGES
- RESEARCH APPROACH
- MARKET SIZING & VALIDATION APPROACH
- DATA TRIANGULATION APPROACH
- MARKET SHARE ESTIMATION
- STUDY ASSUMPTIONS
- LIMITATIONS
- RISK ASSESSMENT
- EXECUTIVE SUMMARY
- CANCER/TUMOR PROFILING: MARKET OVERVIEW
- ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE AND COUNTRY (2021)
- CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- CANCER/TUMOR PROFILING MARKET: REGIONAL MIX (2022-2027)
- CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. EMERGING ECONOMIES (2022 VS. 2027)
- INTRODUCTION
- MARKET DYNAMICS
- INDUSTRY TRENDS
- INTRODUCTION
- IMMUNOASSAYS
- NEXT-GENERATION SEQUENCING
- POLYMERASE CHAIN REACTION
- IN SITU HYBRIDIZATION
- MICROARRAYS
- MASS SPECTROMETRY
- OTHER TECHNOLOGIES
- INTRODUCTION
- BREAST CANCER
- LUNG CANCER
- COLORECTAL CANCER
- PROSTATE CANCER
- MELANOMA
- OTHER CANCERS
- INTRODUCTION
- GENETIC BIOMARKERS
- PROTEIN BIOMARKERS
- OTHER BIOMARKERS
- INTRODUCTION
- RESEARCH APPLICATIONS
- CLINICAL APPLICATIONS
- INTRODUCTION
- NORTH AMERICA
- EUROPE
- ASIA PACIFIC
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- OVERVIEW
- STRATEGIES ADOPTED BY KEY PLAYERS
- REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
- MARKET SHARE ANALYSIS
- COMPANY EVALUATION QUADRANT
- COMPETITIVE SCENARIO
- KEY PLAYERS
- OTHER PLAYERS
- INSIGHTS FROM INDUSTRY EXPERTS
- DISCUSSION GUIDE
- KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
- CUSTOMIZATION OPTIONS
- RELATED REPORTS
- AUTHOR DETAILS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
